SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase (COIN) is trending due to polarized community reactions to its recent Super Bowl commercial, with sentiment sharply divided on its effectiveness amid broader discussions of significant crypto market volatility. The debate continues on whether the stock has found a bottom or is poised for further declines, alongside anticipation for upcoming earnings.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is drawing significant attention following news of its extended $250 million capital runway through 2028, which many believe secures its operations and removes dilution concerns. The community is sharply divided, with bulls anticipating a short squeeze and another historic surge in the blockchain and molecular-marker technology stock, while skeptics argue it remains a "dilution machine" without sustained product revenue.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as the Super Bowl drives massive betting volume and user engagement, with the community actively debating the company's expanding prediction market offerings and the broader sector's evolving regulatory landscape, all ahead of its anticipated earnings report.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after abruptly ceasing its compounded GLP-1 weight-loss pill offering amid intensified FDA scrutiny and legal threats, sparking widespread debate about the company's regulatory risks and strategic direction. The community is sharply divided, with bears pointing to management's judgment and potential lawsuits, while bulls emphasize the removal of legal overhang and the broader telehealth platform's potential for recovery and growth, especially with the upcoming Super Bowl ad.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Community excitement for TG Therapeutics is surging following Christina Applegate's Super Bowl commercial for Briumvi, which is expected to drive substantial patient awareness and market adoption. The authentic endorsement is viewed as a significant catalyst, further differentiating Briumvi amidst competitor safety concerns.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is garnering significant attention following FDA acceptance of its NDA for CTx-1301, a potentially game-changing ADHD treatment, as the community eagerly awaits impending US patent news, fueling speculation of substantial market revaluation due to its low float.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

PZZA is trending due to persistent buyout speculation, with community sentiment driven by reports of private equity offers at a premium to its perceived undervalued share price, alongside discussions of activist investor interest and its attractive dividend yield.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending as futures indicate strong bullish momentum leading into the week, while the community is widely discussing the Super Bowl halftime show's perceived, albeit speculative, impact on market sentiment alongside anticipation for upcoming jobs and inflation reports.

JERRY (JYAI) is a Matt Furie's artistic style; it features an AI-powered content creation hub that produces community-driven video series and art.  Jerry the Turtle, created by Matt Furie, is a character inspired by Furie’s artistic style. JERRY is also an AI-driven meme coin with an ambitious vision. The goal is to establish an AI-powered production house dedicated to creating a video series or episodes featuring characters from Matt Furie’s universe alongside those from Jerry’s world.  This unique blend of characters aims to produce the ultimate crypto-based series. Additionally, we are developing an app that will offer an exclusive, ad-free video series featuring characters from both Matt Furie’s creations and the Jerry Universe. Users will be able to download and share videos directly through the platform.  But that’s not all! A special Jerry Art Panel will showcase original Jerry characters, artwork, and fan creations—free to explore, download, and share with the community.

Jerry The Turtle By Matt Furie

Jerry The Turtle ($JYAI), an AI memecoin backed by Matt Furie, is trending with strong community enthusiasm following new exchange listings on platforms like Bitget and KuCoin Alpha, a recent developer update to counter selling pressure, and an ongoing 12-week marketing campaign including a new podcast and a Crypto Banter partnership, with many anticipating it to be the "next PEPE" and aspiring for Tier 1 exchange listings.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred

STRC is trending as it maintains its position around $100 par value, buoyed by its attractive variable dividend rate of 11.25%, with the community actively debating its role in funding MSTR's Bitcoin strategy and its viability as a high-yield income instrument.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes.</li><li>The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.</li><li>For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data.</li></ul>Pfizer Inc. (PFE) stock was in the spotlight on Tuesday after the company reported positive updates from a study testing weight loss treatment and a better-than expected fourth quarter print.However, <a href="https://stocktwits.com/symbol/PFE">PFE shares</a> were down 2% in pre-market trading on Tuesday as investors appeared to remain cautious about growth risks and the long road ahead for its GLP-1 pipeline.&nbsp;<h2 class="st-heading-2">Positive Topline Results For Weight Loss Treatment&nbsp;</h2>Pfizer reported positive topline results from its Phase 2b VESPER-3 study evaluating PF’3944, an ultra-long-acting injectable GLP-1 receptor agonist, in adults with obesity or overweight without type 2 diabetes.The trial aimed to determine whether patients could maintain weight loss while switching from weekly to once-monthly injections and whether the treatment would retain a favorable safety profile.The study met its primary endpoint, delivering statistically significant weight reduction across all tested doses. Participants achieved up to 12.3% mean placebo-adjusted weight loss at week 28. PF’3944 was generally well tolerated, with mostly mild to moderate gastrointestinal side effects and limited treatment discontinuations. The safety profile remained consistent with the broader GLP-1 drug class.“Based on the monthly dosing efficacy and tolerability demonstrated in this trial, we remain confident in our plan to include a higher 9.6 mg monthly maintenance dose of PF’3944 in Phase 3,” said Jim List, Chief Internal Medicine Officer.Following its acquisition of Metsera and a global licensing deal with YaoPharma, Pfizer said it is accelerating its obesity treatment pipeline. The company plans to launch more than 20 trials in 2026, including 10 Phase 3 studies of PF’3944.<h2 class="st-heading-2">Q4 Earnings Snapshot</h2>Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion and adjusted diluted earnings between $2.80 and $3 per share. The company said the outlook includes roughly $5 billion in expected COVID-19 product sales and a projected $1.5 billion year-over-year revenue hit from certain products losing exclusivity.The company posted a 2% decline in FY2025 revenue at $62.6 billion with adjusted earnings of $3.22 per share.For the fourth-quarter (Q4), Pfizer posted a revenue of $17.6 billion, beating Wall Street estimates of $16.8 billion, according to Fiscal.ai data. It also posted a better-than-expected EPS of $0.66.<h2 class="st-heading-2">What Did Stocktwits Users Say?</h2>Retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours, amid ‘high’ message volumes. PFE was among the top trending tickers on the platform.<figure class="image"><img src="https://news.stocktwits-cdn.com/PFE_jpg_91e98a5cdf.webp" alt="PFE.jpg" width="928" height="111"><figcaption>PFE's Sentiment Meter and Message Volumes in Pre-Market on Feb. 3, 2026 | Source: Stocktwits</figcaption></figure>One user expects multiple upcoming catalysts this year for the stock.<stembedurl>https://stocktwits.com/giuseppe8469/message/643776399</stembedurl>Another user highlighted key support and resistance levels.<stembedurl>https://stocktwits.com/Jas45z/message/643776263</stembedurl>The stock has gained around 1.5% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/sofi-stock-rises-pre-market-what-moving-average-indicates/cZbiqlvR4ln">SOFI Stock Hovers Around 200-DMA — A Make-or-Break Test Looms</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Pfizer’s logo is on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Pfizer Reports Positive Weight-Loss Trial Results, Strong Q4 – So Why Is PFE Stock Falling?

Pfizer reaffirmed its full-year 2026 revenue guidance of $59.5 billion to $62.5 billion, while its FY2025 revenue came in at $62.6 billion.

Equity

Pharma ETF (FTXH) Hits New 52-Week High

Pharma ETF FTXH hits a new 52-week high as industry momentum, rate cuts, and AI adoption lift the sector???signaling potential near-term upside for FTXH investors.



Pharma ETFs in Spotlight Following Robust Q3 Earnings Results

Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month 

As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.  

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

 JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.


Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit

Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.     

ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook

IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.


What Are Wall Street Analysts' Target Price for Bristol-Myers Squibb Stock?

Pharma giant Bristol-Myers Squibb has notably outpaced the broader pharma industry over the past year and analysts remain moderately bullish on the stock’s prospects.

First Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

FTXH
First Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest FTXH News

FTXHFirst Trust Exchange-Traded Fund III - First Trust Nasdaq Pharmaceuticals ETF